Molecular profiles and clinical outcome of stage UICC II colon cancer patients.

PubWeight™: 1.05‹?› | Rank: Top 15%

🔗 View Article (PMID 21465190)

Published in Int J Colorectal Dis on April 05, 2011

Authors

Jörn Gröne1, Dido Lenze, Vindi Jurinovic, Manuela Hummel, Henrik Seidel, Gabriele Leder, Georg Beckmann, Anette Sommer, Robert Grützmann, Christian Pilarsky, Ulrich Mansmann, Heinz-Johannes Buhr, Harald Stein, Michael Hummel

Author Affiliations

1: Department of General, Vascular and Thoracic Surgery, Charité University Medicine Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200, Berlin, Germany. joern.groene@charite.de

Articles cited by this

Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36

Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A (1999) 35.16

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90

Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A (2002) 30.32

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34

Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28

Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics (2002) 20.59

Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet (2005) 17.75

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97

A global test for groups of genes: testing association with a clinical outcome. Bioinformatics (2004) 10.82

Repeatability of published microarray gene expression analyses. Nat Genet (2008) 8.24

Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst (2007) 7.44

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36

LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell (1998) 6.15

arrayQualityMetrics--a bioconductor package for quality assessment of microarray data. Bioinformatics (2008) 5.95

Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12

Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet (2003) 4.58

Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res (2001) 4.50

Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99

False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics (2005) 3.83

Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol (2006) 2.49

Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood (2008) 2.14

Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene (2004) 2.09

Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res (2007) 1.89

Gene expression signature predicts recurrence in lung adenocarcinoma. Clin Cancer Res (2007) 1.80

Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg (2004) 1.71

Gene expressions of HMGI-C and HMGI(Y) are associated with stage and metastasis in colorectal cancer. Int J Colorectal Dis (2009) 1.57

Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res (2006) 1.55

Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat (2008) 1.45

Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics (2007) 1.38

Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem (2000) 1.34

PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis (2002) 1.34

Differential expression of the chemokines GRO-2, GRO-3, and interleukin-8 in colon cancer and their impact on metastatic disease and survival. Int J Colorectal Dis (2010) 1.31

Human epidermal growth factor (EGF) module-containing mucin-like hormone receptor 3 is a new member of the EGF-TM7 family that recognizes a ligand on human macrophages and activated neutrophils. J Biol Chem (2001) 1.16

Loss of Gelsolin expression in human ovarian carcinomas. Eur J Cancer (2005) 1.07

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab. Leukemia (2008) 1.05

Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol (1988) 1.02

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer. BMC Cancer (2008) 0.94

Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett (2004) 0.90

Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer (2005) 0.86

Non-small cell lung carcinoma of the superior sulcus: favourable outcomes of combined modality treatment in carefully selected patients. Lung Cancer (2007) 0.85

Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. Int J Colorectal Dis (2010) 0.81

Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet (2009) 0.77

Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer. Int J Colorectal Dis (2010) 0.76

Articles by these authors

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40

Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood (2011) 7.43

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42

Acupuncture and knee osteoarthritis: a three-armed randomized trial. Ann Intern Med (2006) 4.42

Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology (2003) 3.93

Longevity of materials for pit and fissure sealing--results from a meta-analysis. Dent Mater (2011) 3.56

Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA (2003) 3.39

BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst (2003) 3.37

The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23

Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia (2005) 3.16

Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol (2003) 3.09

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood (2013) 3.03

Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood (2007) 2.82

Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res (2009) 2.75

Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. J Am Coll Cardiol (2006) 2.73

Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults. Gastroenterology (2013) 2.71

Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood (2008) 2.66

DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem (2007) 2.65

Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65

Multiple levels of regulation of the interleukin-6 system in stroke. Stroke (2003) 2.61

Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem (2009) 2.57

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res (2008) 2.56

Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol (2003) 2.54

An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood (2008) 2.46

Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One (2008) 2.46

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet (2012) 2.43

ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40

Predictors of overweight during childhood in offspring of parents with type 1 diabetes. Diabetes Care (2009) 2.31

Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol (2005) 2.31

WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol (2003) 2.30

GlobalANCOVA: exploration and assessment of gene group effects. Bioinformatics (2007) 2.24

Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21

Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood (2006) 2.19

CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res (2003) 2.15

MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med (2009) 2.12

Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10

Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07

Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med (2013) 2.07

Course of platelet activation markers after ischemic stroke. Stroke (2002) 2.05

Factors affecting and affected by user acceptance of computer-based nursing documentation: results of a two-year study. J Am Med Inform Assoc (2003) 2.05

Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood (2002) 2.03

Elevated NF-kappaB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood (2005) 2.00

Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J (2002) 2.00

New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol (2005) 1.96

Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med (2010) 1.93

Neuroendocrine tumors of the pancreas. Oncologist (2009) 1.91

Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol (2012) 1.90

Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. Blood (2005) 1.90

Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene (2005) 1.89

MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS One (2010) 1.89

Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther (2006) 1.88

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A (2013) 1.88

Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS One (2011) 1.87

CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol (2002) 1.85

Sentinel lymph node biopsy in colon cancer: a prospective multicenter trial. Ann Surg (2007) 1.79

Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol (2012) 1.75

The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood (2013) 1.71

Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 1.70

Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69

Multiple testing on the directed acyclic graph of gene ontology. Bioinformatics (2008) 1.69

A prospective randomized study to assess the efficacy of a surgical sealant to treat air leaks in lung surgery. Eur J Cardiothorac Surg (2009) 1.68

Strong gametocytocidal effect of methylene blue-based combination therapy against falciparum malaria: a randomised controlled trial. PLoS One (2009) 1.68

Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer. Clin Cancer Res (2006) 1.66

Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature (2013) 1.66

Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med (2002) 1.66

The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol (2009) 1.62

Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke (2006) 1.60

Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol (2002) 1.59

International study on low-grade primary central nervous system lymphoma. Ann Neurol (2006) 1.59

Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood (2008) 1.58

Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program (2003) 1.56

IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. Blood (2013) 1.55

ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate (2003) 1.54

Tumor stroma-derived TGF-beta limits myc-driven lymphomagenesis via Suv39h1-dependent senescence. Cancer Cell (2010) 1.53

Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol (2005) 1.51

Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med (2007) 1.51

Tumor infiltrated hilar and mediastinal lymph nodes are an independent prognostic factor for decreased survival after pulmonary metastasectomy in patients with renal cell carcinoma. J Urol (2010) 1.49